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ARTICLE OPEN
Heterogeneity and efficacy of antipsychotic treatment
for schizophrenia with or without treatment resistance:
a meta-analysis
Yuya Mizuno 1,2, Robert A. McCutcheon 1,3,4, Stefan P. Brugger3,4,5,6,7 and Oliver D. Howes1,3,4
Two important clinical questions are whether there is a subtype of schizophrenia which responds differently to clozapine relative to
other antipsychotics, and whether greater efficacy of clozapine is dependent on the degree of treatment-resistance. The authors
address this by examining both variability and magnitude of response in patients treated with clozapine and other antipsychotics
for both treatment-resistant schizophrenia (TRS) and non-resistant schizophrenia. Double-blind randomised controlled trials
comparing clozapine with other antipsychotics in patients with schizophrenia were identified using five databases. Standard
deviations and means of change in total, positive, and negative symptoms were extracted. Variability ratio (VR) and coefficient of
variation ratio (CVR) were used to quantify relative variability in symptom change. Hedges’ g was used to quantify mean differences.
Ten TRS studies (n= 822) and 29 non-TRS studies (n= 2566) were meta-analysed. Relative variability in change of total symptoms
did not differ significantly between clozapine and other antipsychotics in TRS studies (VR= 1.84; 95%CI, 0.85–4.02). These findings
were similar with CVR, and for positive and negative symptoms. Clozapine was superior to other antipsychotics in improving total
symptoms in both TRS (g= 0.34; 95%CI, 0.13–0.56) and non-TRS (g= 0.20; 95%CI, 0.08–0.32) studies. Furthermore, clozapine was
superior in improving positive symptoms in both study groups, but not for negative symptoms. Pooled effect sizes showed no
significant difference between TRS and non-TRS studies. These findings do not support a subtype of schizophrenia which responds
specifically to clozapine. Clozapine is more effective than other antipsychotics irrespective of treatment-resistance, arguing for its
use more generally in schizophrenia. PROSPERO CRD42018086507
Neuropsychopharmacology (2019) 0:1–10; https://doi.org/10.1038/s41386-019-0577-3
INTRODUCTION
Schizophrenia is a severe mental illness with a lifetime prevalence
of approximately 0.7% [1]. It is characterised by psychotic
symptoms, including delusions and hallucinations, negative
symptoms including, amotivation and social withdrawal, and
cognitive impairment. Antipsychotic drugs remain the cornerstone
of treatment for schizophrenia [2, 3]. However, there is hetero-
geneity in how patients respond to antipsychotics from the early
stages of illness [4, 5]. About one-third of patients have treatment-
resistant schizophrenia (TRS) [6], defined as inadequate response
to two or more trials of first-line (non-clozapine) antipsychotic
treatment at adequate dose and duration [7]. Treatment-
resistance is a major challenge to clinical management, and is
associated with high medical costs and increased disability
relative to schizophrenia in general [8].
A landmark clinical trial in 1988 established clozapine as
superior to other antipsychotics in treating TRS [9]. For over two
decades since then, clozapine has had a unique position as the
only medication licensed for patients with TRS [10]. Furthermore,
clozapine treatment is associated with reduced hospitalisations
[11] and long-term mortality [12] relative to other antipsychotics.
However, a recent network meta-analysis of therapy for TRS
utilising both direct and indirect comparisons between antipsy-
chotics showed no difference between clozapine and most other
antipsychotics [13]. This has challenged clozapine’s unique
position in the therapeutic arsenal for schizophrenia.
Subsequently, a systematic review by the Treatment Response
and Resistance in Psychosis (TRRIP) working group found that in
50% of clinical trials of antipsychotics for TRS it was unclear how
TRS was established [7]. Furthermore, a number of clinical trials
included patients who were intolerant rather than treatment-
resistant to previous antipsychotic treatment [7]. Heterogeneity in
study populations due to variability in inclusion criteria and/or the
inclusion of patients with treatment-intolerance as well as TRS
may obscure the superiority of a therapy for TRS. Recent network
[13] and conventional [14] meta-analyses comparing antipsycho-
tics in TRS have selected studies based on broad definitions of
treatment-resistance, later accounting for study characteristics in
sensitivity analyses. However, no meta-analyses have compared
the efficacy of clozapine between studies of strictly-defined TRS
and studies of schizophrenia not exclusive for treatment-
resistance. Furthermore, none have examined the association
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between the rigour in definitions of TRS based on the TRRIP
consensus criteria [7] and clozapine’s efficacy. These investigations
are crucial in establishing clozapine’s efficacy in treatment-
resistant illness.
If treatment is specifically effective for a condition, in addition to
showing a greater improvement, it should also show a more
homogenous response relative to comparator drugs that are not
effective (e.g. TRS patients treated with clozapine show consistent
improvement, whereas those receiving other antipsychotics
respond more variably). Alternatively, if treatment is specifically
effective for a subgroup of patients with the condition, it will result
in a more variable response compared to medications that are not
effective (e.g., a subgroup of TRS patients improve significantly
with clozapine, whereas those receiving other antipsychotics show
a more consistent pattern of minimal change). This can be
determined by measuring the variability of response. Nakagawa
et al. proposed a novel method to meta-analyse variability [15],
which we recently used to compare variability between regional
brain structure [16] and drug-placebo response [17] in
schizophrenia.
We, therefore, set out to address the question of whether
clozapine’s superior efficacy is more evident in strictly-defined
TRS, and whether this population shows a more homogenous
response to clozapine relative to other antipsychotics. First, we
carried out a meta-analysis of variance using data from published
double-blind randomised controlled trials to test if a difference in
variability of symptom change exists in TRS patients receiving
clozapine compared to other antipsychotics. Next, we conducted a
meta-analysis of mean difference to compare the effects of
clozapine relative to other antipsychotics between patients with
TRS and patients not exclusive for treatment-resistance. Finally, we
used meta-regression to investigate if the rigour in definitions of
TRS is a moderator of clozapine’s efficacy. Consistent with the
hypothesis that clozapine shows greater efficacy for strictly-
defined TRS, we hypothesised that (1) the variability in symptom
change would be smaller with clozapine treatment relative to
other antipsychotics in TRS patients (Fig. 1), (2) the effects of
clozapine would be significantly larger in studies of TRS relative to
those of patients not exclusive for TRS, and (3) clozapine would
show greater efficacy in studies with more rigorous criteria for
determining TRS.
MATERIALS AND METHODS
This study adhered to the preferred reporting items for systematic
reviews and meta-analyses (PRISMA) statement (Table S1) [18],
and was registered with the PROSPERO international prospective
register of systematic reviews (CRD42018086507) [19]. The full
protocol, including detailed methods, is provided in the supple-
ment. Two authors (YM and RM) independently undertook the
literature search, identified eligible studies, extracted data, and
assessed risk of bias of individual studies. Disagreements during
these procedures were resolved through discussion with a third
author (OH).
Study selection
Studies from inception to October 18, 2018 were searched using
EMBASE, Medline, PsycINFO, ClinicalTrials.gov, and Cochrane
CENTRAL. Search terms included synonyms of clozapine, RCT,
and schizophrenia (Supplementary Materials and Methods). No
limits were applied in the search. Reference lists of relevant
studies and review articles were hand-searched for additional
studies. Double-blind randomised controlled trials comparing
clozapine with any other antipsychotic medication in patients with
schizophrenia were included. We excluded studies where the
primary publication was not reported in English, single-blind or
Fig. 1 Hypothesised result for the meta-analysis of variance in patients with strictly-defined treatment-resistant schizophrenia (TRS).
The trajectory of symptom change for TRS patients treated with clozapine and other antipsychotics are illustrated in green and red,
respectively. The vertical arrows represent the pooled variability of symptom change within each treatment group.
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placebo-controlled trials, and studies that did not report on
change in psychopathology. When there were multiple publica-
tions based on overlapping participants, the publication with the
largest sample, longest duration of intervention, and/or most
detailed data regarding change in psychopathology was selected.
Data extraction
For the meta-analysis of variance, the primary outcome measure
was the standard deviation (SD) of change in total symptoms as
measured by the brief psychiatric rating scale (BPRS) [20] or the
positive and negative syndrome scale (PANSS) [21]. For the meta-
analysis of mean difference, the primary outcome measure was
the mean change in total symptoms as measured by the BPRS/
PANSS. Secondary outcome measures included SD of change
and mean change in positive and negative symptoms as
measured by the BPRS/PANSS subscales, the scale for the
assessment of positive symptoms (SAPS) [22], or the scale
for the assessment of negative symptoms (SANS) [23]. Further-
more, the following variables were extracted: authors, year of
publication, participant characteristics (age, duration of illness,
treatment setting, definition of TRS where applicable), study
duration, parallel or crossover design, clozapine dose, name and
dose of comparator antipsychotic, industry sponsorship, and
mean ± SD total, positive, and negative symptom scores at
baseline and endpoint. Doses of antipsychotics were converted
into chlorpromazine equivalents (CPZE) using formulas described
by Andreasen and colleagues [24]. Where relevant data were
missing from the primary publication, data were extracted from
related publications from the same study. Corresponding authors
were contacted for additional data if SD of change in symptom
scores were unreported. Only original values for SD of change in
symptom scores were used in the meta-analysis of variance, as this
was the primary outcome measure. For the meta-analysis of mean
difference, missing values regarding SD of change were imputed
(Supplementary Materials and Methods).
Study categorisation
Studies were categorised into those strictly of TRS patients
(TRS studies) and those that included patients not exclusive for
TRS (non-TRS studies). To be included in the TRS group, studies
were required to only include patients who were resistant to
previous antipsychotic treatment. Studies which included patients
with treatment-intolerance, relapse following non-adherence, or
other non-treatment-resistant forms of schizophrenia were
defined as non-TRS studies. TRS studies were further assessed
for the rigour with which TRS was assessed by determining the
number of criteria required to define TRS that were met. The TRRIP
consensus minimum criteria for TRS which specify a total of eight
items were used (Supplementary Materials and Methods) [7].
Criteria were weighted equally and summed to determine the
total number that were used in assessment of TRS in a
given study.
Data synthesis
Risk of bias of individual studies was assessed using the Cochrane
Collaboration’s Tool for Assessing Risk of Bias [25]. For the meta-
analysis of variance, SD of change in symptom scores was pooled
across studies to calculate the log variability ratio (lnVR) [15] using
the method we applied to brain structural variability in schizo-
phrenia [16] (Supplementary Materials and Methods).
In biological systems, the dependence between the mean and
variance is common, in which larger mean values are associated
with greater variance [26]. Therefore, a between-group difference
in relative variability, as indexed with lnVR, may in part reflect a
between-group difference in the mean. Thus, we calculated a
complementary measure of relative variability which accounts for
the difference in means, the log coefficient of variation ratio
(lnCVR) [15]. See the supplement and Brugger and Howes 2017
[16] for a full description.
For the meta-analysis of mean difference, we calculated Hedges’
g to quantify between-group differences in mean effects across
TRS and non-TRS studies.
Statistical analysis
SPSS Statistics Version 24 (IBM Corp., Armonk, NY, USA) was used
to compare characteristics of included studies using the
Mann–Whitney U and chi-squared tests. Meta-analyses were
performed in R 3.4.0 [27] using the metafor package [28]. Primary
outcomes relating to variance and mean difference were pooled
across studies using univariate random-effects models. Meta-
analyses of secondary outcomes relating to positive and negative
symptoms were conducted in similar fashion. To assist interpreta-
tion of findings for the meta-analysis of variance, summary effect
sizes for lnVR and lnCVR were transformed back to a linear scale
(Supplementary Materials and Methods) [16].
A VR (or CVR) of 1 can be interpreted as equal variability in the
clozapine and other antipsychotics groups, whereas a larger (or
smaller) value would indicate greater (or lower) variability in the
clozapine group. For the meta-analysis of mean difference,
Hedges’ g across TRS and non-TRS studies were compared using
a Wald-type test. All statistical tests were carried out at a two-
tailed alpha-level of 0.05.
Sensitivity analysis and meta-regression
To investigate the robustness of our findings, we carried out a
priori sensitivity analyses excluding studies focusing on child and
adolescent patients, excluding studies with crossover designs, and
for the meta-analysis of mean difference, excluding studies with
imputed SD of change values. Furthermore, for the meta-analysis
of mean difference, we carried out post hoc sensitivity analyses
excluding studies published before 1988 when clozapine’s super-
iority in TRS was first demonstrated [9], disaggregating studies
including both TRS and treatment-intolerant patients from non-
TRS studies, categorising studies based on industry sponsorship,
and examining pairwise comparisons with individual antipsycho-
tics where two or more studies were available. For meta-
regression, we tested the effects of the number of TRS criteria
met, baseline symptom severity, clozapine dose, difference
between CPZE dose of comparator antipsychotic and clozapine,
and duration of double-blind intervention as potential moderators
of effect sizes using univariate mixed-effects meta-regression.
PANSS total scores were used for baseline symptom severity, with
BPRS total scores converted using conversion tables [29].
Inconsistency and publication bias
Inconsistency between studies was assessed using the I2 statistics,
with I2 greater than 50% indicating moderate to high incon-
sistency. Publication bias was assessed by visual inspection of
funnel plots and regression tests for funnel plot asymmetry.
RESULTS
Study characteristics
Thirty-nine studies met inclusion criteria for the meta-analysis
(Fig. S1). Characteristics of the included studies are summarised in
Table 1. Ten TRS studies [9, 30–38] and 29 non-TRS studies [39–67]
were included with a total of 3388 patients (822 and 2566,
respectively). The average age of participants (p= 0.003), average
dose of clozapine (p= 0.002), and average dose of comparator
antipsychotics (p= 0.045) were significantly higher in TRS studies
compared to non-TRS studies. When compared within study
groups, the average daily dose of comparator antipsychotics in
CPZE was significantly greater relative to clozapine for both
TRS (z= 3.033, p= 0.002) and non-TRS (z= 4.099, p < 0.001)
Heterogeneity and efficacy of antipsychotic treatment for schizophrenia. . .
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studies. Details regarding individual studies are summarised in
Tables S2 and S3.
Definitions of failed adequate treatment trials varied between
TRS studies. One study [9] with rigorous criteria required
inadequate response to three previous antipsychotic trials and
one prospective trial with haloperidol, while two studies [34, 38]
only required at least one failed antipsychotic trial. Only three TRS
studies [9, 33, 35] fulfilled all the TRRIP consensus criteria [7] for
adequate dose, duration, and number of previous antipsychotic
trials, and none fulfilled criteria for past adherence.
Twelve studies mixed treatment-intolerant patients with
treatment-resistant patients, and were, therefore, categorised
as non-TRS studies [39–50]. Of the remaining 17 studies which
did not select patients for TRS, patient characteristics varied with
two studies including first-episode or drug-naïve patients
[60, 68], while others included patients with chronic illness
[57, 62, 67].
Risks for bias in individual studies are summarised in Table S4.
Details regarding random sequence generation and allocation
concealment were often unreported, resulting in “unclear risk” for
selection bias in eight TRS (80%) and 25 non-TRS studies (86%).
Similarly, few studies clearly stated blinding of outcome assessors,
resulting in “unclear risk” for detection bias in eight TRS (80%) and
21 non-TRS studies (72%). Overall, only three non-TRS studies
[48, 49, 62] showed “low risk” for bias in all criteria.
Meta-analysis of variance
Fifteen studies (n= 1492) reporting original values for SD of
change in symptom scores were included in this meta-analysis.
For the primary outcome, the variability ratio (VR) for change in
total symptoms did not differ significantly between clozapine and
other antipsychotics in TRS [9, 30, 35, 37] (N= 4, VR= 1.84; 95%
confidence interval (CI), 0.85–4.02; p= 0.124), or non-TRS studies
[40, 43–48, 50, 65–67] (N= 11, VR= 0.98; 95%CI 0.90–1.06; p=
0.589) (Fig. 2a). Comparison of the pooled VR between TRS
and non-TRS studies showed no significant difference (z=−1.587,
p= 0.112).
There were significant positive correlations between the
adjusted mean change and SD of change in total, positive and
negative symptom scores (all p < 0.05) (Fig. S2), suggesting mean
scaling of variability. However, when the coefficient of variation
ratio (CVR) was used to account for the difference in means, no
significant difference in variability of symptom change was
observed between clozapine and other antipsychotics across
TRS (CVR= 1.66; 95%CI, 0.74–3.71; p= 0.220), or non-TRS (CVR=
0.97; 95%CI, 0.89–1.05; p= 0.447) studies (Fig. 2b). There was no
significant difference in CVR between TRS and non-TRS studies
(z= 1.299, p= 0.194). Similarly, for the secondary outcomes of
positive and negative symptoms, no significant difference in VR or
CVR was found in TRS studies [9, 30, 35, 37] (Figs. S3 and S4, all p >
0.05). Variability in positive symptom change was significantly
lower with clozapine than other antipsychotics in non-TRS studies
[42–46, 48, 50, 53, 65, 66] (VR= 0.92; 95%CI, 0.84–0.99; p= 0.031);
but not after accounting for mean-scaling (CVR= 0.90; 95%CI,
0.77–1.05; p= 0.170).
Sensitivity analyses relating to change in total, positive, and
negative symptoms were consistent with the main results
regarding VR and CVR (Table S5). The number of items fulfilled
in the TRRIP consensus criteria [7] was a significant moderator of
VR (z= 2.790, p= 0.005) and CVR (z= 2.245, p= 0.025), indicating
that studies that met more of the TRRIP criteria for TRS were
associated with greater variability in the clozapine arm for change
of total symptoms (Fig. S5).
Meta-analysis of mean difference
For the primary outcome of total symptoms, 10 TRS studies
[9, 30–38] (n= 713) and 28 non-TRS studies [39–60, 62–67] (n=
2415) were included in the meta-analysis. Clozapine was superior
to other antipsychotics in improving total symptoms for both TRS
(g= 0.34; 95%CI, 0.13–0.56; p= 0.002) and non-TRS (g= 0.20; 95%
CI, 0.08–0.32; p= 0.001) studies (Fig. 3). For secondary outcomes,
clozapine showed greater improvement in positive symptoms in
both TRS (g= 0.32; 95%CI 0.11–0.54; p= 0.003) and non-TRS (g=
0.15; 95%CI 0.04–0.25; p= 0.006) studies (Fig. S6). However, this
was not evident for negative symptoms in either TRS (g= 0.22;
95%CI −0.07–0.52; p= 0.135) or non-TRS (g= 0.07; 95%CI
−0.05–0.19; p= 0.262) studies (Fig. S7). The comparison of the
pooled effect sizes between TRS and non-TRS studies showed no
significant difference for change in total symptoms (z=−1.105;
p= 0.269), positive symptoms (z=−1.478, p= 0.139), or negative
symptoms (z=−0.962; p= 0.336).
A priori sensitivity analyses for both TRS and non-TRS studies
were largely consistent with our main finding of clozapine being
superior to other antipsychotics in improving total and positive
symptoms (Tables S6 and S7). However, when studies with
imputed SD of change values were excluded from non-TRS
Table 1. Characteristics of included studies.
TRS studies (N= 10) Non-TRS studies (N= 29) Comparisons, statistic/p-value
Year published, range 1988–2016 1974–2011
Design of double-blind randomised controlled trial, N Parallel 9, Crossover 1 Parallel 27, Crossover 2
Including child and adolescent patients, N 0 3
Total number of participants, median (range) 56 (13–267) 51 (15–423) z=−0.290, p= 0.788
Average age of participants, median (range) 38.1 (35.0–42.0) 34.0 (12.3–66.5) z=−2.890, p= 0.003
Duration of double-blind intervention (weeks), median
(range)
11 (6–29) 8 (4–52) z=−1.170, p= 0.258
Total number of treatment arms compared with clozapine 12 33
Breakdown of comparator arms (drug type and number
of comparisons)
OLZ 4, HAL 3, RIS 3, CPZ 2 CPZ 9, HAL 8, OLZ 7, RIS 5,
FLU 1, REM 1, ZIP 1, ZTP 1
χ(7)= 2.871, p= 0.897
Average dose of clozapine (mg/day), median (range) 490 (325–618) 304 (155–800) z=−2.960, p= 0.002
Average dose of comparator drug in CPZEa (mg/day),
median (range)
953 (385–1413) 503 (196–1642) z=−2.007, p= 0.045
p-values of <0.05 are shown in bold.
CPZ chlorpromazine, CPZE chlorpromazine equivalents, FLU fluphenazine, HAL haloperidol, OLZ olanzapine, REM remoxipride, RIS risperidone, TRS treatment-
resistant schizophrenia, ZIP ziprasidone, ZTP zotepine.
aCalculated using formulas reported by Andreasen et al. [24]
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Fig. 2 Forest plot showing variability ratios (VR) and coefficient of variation ratios (CVR) for change in total symptoms in studies of
clozapine relative to other antipsychotics for the treatment of patients with strictly-defined treatment-resistant schizophrenia (TRS) and
other non-refractory schizophrenia (non-TRS). In studies of TRS, there is no significant alteration in the summary variability ratio (VR= 1.84,
p= 0.124), indicating that the variability in response to treatment is the same in patients receiving clozapine as other antipsychotics.
Furthermore, there is no significant alteration in the summary coefficient of variation ratio (CVR= 1.66, p= 0.220), indicating that the
variability in response to treatment is the same in patients receiving clozapine as other antipsychotic drugs after adjusting for greater
symptomatic improvement in the clozapine group. Similarly, the variability in response to treatment is the same in patients receiving
clozapine relative to other antipsychotics in studies of non-TRS. CI, confidence interval; HAL, haloperidol; OLZ, olanzapine; RE, random effects;
RIS, risperidone.
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studies, clozapine was no longer superior to other antipsychotics
in improving total symptoms (g= 0.12; 95%CI −0.05–0.28; p=
0.178). When studies including both TRS and treatment-intolerant
patients were disaggregated from the non-TRS studies, clozapine
was superior in the remaining studies for improving total
symptoms (g= 0.31; 95%CI 0.12–0.49; p= 0.001), but not for
positive symptoms (g= 0.17; 95%CI −0.06–0.41; p= 0.154). Post
hoc sensitivity analyses regarding industry sponsorship and
pairwise comparisons with individual antipsychotics resulted in
few studies for each comparison. The results indicate that
clozapine’s superiority in improving total and positive symptoms
is driven by studies sponsored by manufacturers of clozapine, and
comparisons with chlorpromazine and haloperidol (Tables S6 and
S7). Regarding change in total symptoms, funnel plots and
regression tests indicated potential publication bias in non-TRS
studies (z= 2.557, p= 0.011), but not in TRS studies (z=−0.734,
p= 0.463) (Fig. S8). A trim and fill analysis suggested the presence
of eight missing non-TRS studies which do not support the
superiority of clozapine (Fig. S8b).
Meta-regression
For total symptoms, mean daily dose of clozapine (z= 1.959, p=
0.050) and duration of intervention (z=−2.169, p= 0.030) were
significant moderators of effect size, with greater dose of
clozapine and shorter study duration associated with greater
improvements with clozapine relative to other treatments (Fig. S9).
The number of items fulfilled in the TRRIP consensus criteria [7]
(z= 0.911, p= 0.362), baseline symptom severity (z= 1.679, p=
0.093), and difference between CPZE dose of comparator
antipsychotic and clozapine (z= 1.733, p= 0.083) were not
significant moderators of clozapine’s efficacy relative to other
antipsychotics for total symptoms (Fig. S9). Different patterns
regarding moderators of effect sizes were apparent for positive
and negative symptoms (Figs. S10 and S11). TRS studies, and in
particular more rigorously-defined TRS was linked to greater
improvement in positive symptoms with clozapine compared to
other antipsychotics (z= 2.168, p= 0.030). A higher mean dose
of clozapine in trials was associated with greater improvement
in both positive (z= 3.403, p < 0.001) and negative (z= 3.797,
p < 0.001) symptoms for patients receiving clozapine. All
other associations in the meta-regression were non-significant
(all p > 0.05).
Potential treatment-resistance in non-TRS studies
The definition of TRS requires at least two adequate trials of
different antipsychotic drugs. A corollary of this is that at first
presentation it is not possible to prospectively know if the illness is
TRS or not, as this can only be determined retrospectively after
two adequate treatment trials. Recent retrospective evidence
indicates that 70–84% of patients ultimately diagnosed with TRS
showed limited response from illness onset [69, 70]. This implies
that non-TRS studies that included patients early in the course of
illness, before it is possible to determine if the illness is treatment-
resistant or not, may have included patients subsequently
established to be TRS, confounding our analyses. To examine
this, we carried out additional post hoc analyses for the non-TRS
studies. First, we reviewed the non-TRS studies and excluded
those which had set out to include both TRS and treatment-
intolerant patients [39–50]. Of the 17 non-TRS studies remaining,
two further studies were excluded due to descriptions of
participants that indicated they included treatment-resistant
patients [62, 63], to leave 15 studies. Of the remaining studies,
fourteen reported on change in total symptoms in a total
sample of 848 patients [51–60, 64–67]. We repeated the meta-
analysis in this sample free of TRS patients as far as it is possible to
ascertain from the trial descriptions, and found a significantly
larger mean improvement in total symptoms with clozapine
relative to other antipsychotics (g= 0.31; 95%CI 0.11–0.52;
p= 0.003). We next examined if the duration of illness was a
moderator of effect size in these studies to test if studies including
more patients early in the course of illness, which may indicate a
higher proportion of patients undiagnosed with TRS, showed
larger effects of clozapine. However, meta-regression indicated
that duration of illness in these studies was not a significant
moderator of effect size (Fig. S12, z=−0.158, p= 0.874).
DISCUSSION
Our first main finding is that there is no significant difference in
the variability in the effectiveness of clozapine compared to other
antipsychotics in patients with either treatment-resistant or non-
TRS, indicating similar heterogeneity in response across antipsy-
chotics and patient groups. Our second main finding is that
clozapine is superior to other antipsychotics in improving total
and positive symptoms both in patients with TRS and non-TRS,
with no significant difference in effect sizes between the two
groups. Our third main finding is that more rigorously-defined
treatment-resistance is associated with greater improvement in
positive symptoms, but not total and negative symptoms, with
clozapine. Our findings that variability in response is no different
with clozapine, and that clozapine is more effective in non-TRS
studies are contrary to our hypothesis that clozapine is specifically
effective in TRS. In contrast, the finding that more rigorously-
defined TRS is linked to greater improvement in positive
symptoms may suggest additional benefit of clozapine in
treatment-resistance.
To the best of our knowledge, there is only one meta-analysis
comparing the effectiveness of clozapine relative to other
antipsychotics directly between patients with treatment-resistant
and non-resistant schizophrenia. Wahlbeck et al. [71] compared
clozapine to first-generation antipsychotics across 30 randomised
controlled trials, seven of which included treatment-resistant
patients. Patients receiving clozapine were more likely to achieve
“clinical improvement” as defined by individual studies, in studies
of both TRS and non-resistant schizophrenia. However, it was
unclear in this study how TRS studies were defined, there was no
distinction between treatment-resistance and treatment-intoler-
ance, and single-blind trials were included. While our meta-
analysis supports the finding from this previous report [71], our
study extends these findings by utilising international consensus
guidelines on defining treatment-resistance [7], distinguishing
studies including patients with treatment-intolerance, focusing
on double-blind randomised controlled trials to minimise bias,
and including 18 studies of second-generation antipsychotics
(n= 1630).
Our findings are also broadly in line with a network meta-
analysis by Leucht et al. [72] that showed clozapine was ranked as
the most efficacious antipsychotic for acute treatment of schizo-
phrenia in general, but not those of another network meta-analysis
focusing on trials of treatment-resistance [13]. The latter study
concluded that clozapine was not superior to most other drugs for
TRS, particularly second-generation antipsychotics. While the
conclusion regarding second-generation antipsychotics is sup-
ported by our analysis of pairwise comparisons, several methodo-
logical factors may account for the difference between findings in
this study [13] and our findings. For example, the landmark study
by Kane et al. [9] was excluded to resolve inconsistency in the
network meta-analysis, and studies that included treatment-
intolerant patients were included. Moreover, where SD of change
in symptom scores were not reported, the authors extracted mean
± SD symptom scores at study endpoint while we used the
reported mean change and imputed the missing SD of change
value. Regarding TRS, our effect sizes for total, positive, and
negative symptoms are also broadly in line with those reported by
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Siskind and colleagues [14] which included single-blind trials and
studies including patients with treatment-intolerance.
Strengths and limitations
The current study combined meta-analyses of variance and mean
difference to investigate clozapine’s specificity in relation to TRS.
Unlike previous meta-analyses, we only included double-blind
randomised controlled trials to minimise bias associated with
open-label treatment. Our meta-analysis was designed to address
specific a priori hypotheses, and was not intended to be a
comprehensive meta-analysis regarding clinical outcomes (e.g.,
cognitive function, relapse) and drug safety. Our meta-analysis of
variance was limited by the number of studies reporting SD of
change values for symptom change. Furthermore, our post hoc
sensitivity analyses, particularly those regarding industry sponsor-
ship and individual antipsychotics, resulted in a small number of
studies included in each comparison. This limitation was especially
relevant for TRS studies and thus findings should be interpreted in
the context of limited power. Additionally, the I2 value indicated
high inconsistency in studies included in the meta-analysis of
variance. This was primarily due to a single study [30] reporting
greater SD of change values in symptom change for patients
treated with clozapine relative to chlorpromazine. It was unclear
how the nature of this study differed from others; however,
excluding this study decreased the I2 to <50%. Finally, we
uniformly categorised studies including treatment-intolerant
patients alongside treatment-resistant patients as non-TRS studies.
Although it would have been ideal to extract data specifically
referring to TRS patients from these studies and include them in
the analysis of TRS, this was not possible from the reported data.
General limitations of the literature include the small proportion
of included studies which were judged to have “low risk” of bias as
double-blind trials. Furthermore, we were only able to include
10 studies of strictly-defined TRS, and only a few studies applied
rigorous definitions of TRS. These limitations implicate the need
for better design in future studies, with treatment-resistant
Fig. 3 Forest plot showing the standardised mean difference (SMD) for change in total symptoms in studies of clozapine relative to other
antipsychotics for the treatment of patients with strictly-defined treatment-resistant schizophrenia (TRS) and other non-refractory
schizophrenia (non-TRS). Clozapine was significantly more effective in both studies of TRS (g= 0.34, p= 0.002), and non-TRS (g= 0.20,
p= 0.001). CI, confidence interval; HAL, haloperidol; OLZ, olanzapine; RE, random effects; REM, remoxipride; RIS, risperidone.
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patients selected according to international guidelines [7].
Another general potential issue that affects all trials and meta-
analyses is that the most severely ill patients are likely to be
underrepresented in double-blind randomised controlled trials.
For example, only half of the studies in our meta-analysis included
patients with a total PANSS equivalent of 95 or greater, which is a
benchmark of “markedly ill” to “severely ill” conditions [73].
However, our meta-regression indicated that greater illness
severity is not necessarily related to greater benefits with
clozapine. Finally, with regard to the non-TRS studies, it is possible
that studies that included patients early in the course of illness,
before they had received two adequate trials of different
antipsychotics, may have included patients who were subse-
quently established to be treatment-resistant, potentially con-
founding our analyses. However, we found no significant
relationship between duration of illness and the effect size for
clozapine over other antipsychotics, which indicates that this is
unlikely to be a major confound. Moreover, when clozapine has
been compared with chlorpromazine in treatment-naïve first-
episode patients, before TRS can be established, there has not
been a marked difference in symptom improvement between
drugs [64], contrary to expectations if the inclusion of patients
with unrecognised TRS in this cohort favours clozapine. Never-
theless, it would be useful if future studies of patients early in the
course of their illnesses included follow-up to determine the
number of patients whose illness subsequently met TRS criteria.
This would provide better characterisation of samples and enable
sub-analyses to test if effects of treatments are different in TRS or
non-TRS groups. Another strategy could be to use biomarkers to
identify patients who may have TRS to either exclude them or
enrich samples for studies of TRS. There is evidence that imaging
measures, such as for dopamine, glutamate and resting-state
connectivity may be useful for this [74–77]. A general issue we
identified in many studies is limited sample characterisation (e.g.
nature of previous antipsychotic treatment and patients’ response,
the proportion of patients with acute relapse following non-
concordance to treatment vs. those unwell in the context of
ongoing treatment). Such information is important not just to
permit analyses such as ours, but also to enable clinicians to
determine how generalisable study findings are to clinical practice
[7]. It would be useful if these details were reported in all clinical
trials of antipsychotics for these reasons.
Interpretation and implications
Taken together, the most parsimonious explanation for our
findings is that clozapine is more effective for total and positive
symptoms of schizophrenia irrespective of whether patients have
treatment-resistance or not. Clozapine’s unique efficacy may be
attributable to a number of mechanisms including polypharma-
cology [78, 79] and rapid dissociation from dopamine D2
receptors [80]. While clozapine’s precise mechanism of action
remains unknown, our findings suggest that this action is not
necessarily specific to the neurobiology underlying treatment-
resistance, and is applicable to schizophrenia in general. Of note,
our findings should be interpreted in the context of potential
sponsorship bias, and publication bias particularly for studies of
non-resistant schizophrenia.
In terms of clinical implications, our findings show that clozapine
is consistently superior in both treatment-resistant and non-
resistant schizophrenia. While few moderators reached statistical
significance in our meta-regression, higher clozapine doses were
associated with greater benefits with clozapine for total, positive
and negative symptoms. While this indicates a potential dose-
response relationship, there is still limited evidence regarding the
optimal dosing of clozapine [81]. Furthermore, only a few studies
included in this meta-analysis [39, 43, 48, 49] reported on blood
concentrations of clozapine. Observational studies show clozapine
use is associated with reduced mortality in patients with
schizophrenia [82], but it is generally underused in clinical care
[83, 84]. A recent large-scale trial examining the effects of switching
antipsychotic medications in first-episode schizophrenia found
little benefit in switching between first-line antipsychotics [85].
While challenges in carrying out such studies need to be
acknowledged, our findings indicate that more research is
warranted on the use of clozapine in patients without established
treatment-resistance, especially in early stages of illness.
CONCLUSIONS
We did not find a systematic difference regarding variability of
symptom change in TRS patients treated with clozapine and other
antipsychotics. Furthermore, clozapine’s superiority in improving
total and positive symptoms was not limited to patients with TRS,
and was also evident in patients without established treatment-
resistance. The rigour with which treatment-resistance was
defined was directly associated with greater improvement in
positive symptoms, but not with improvements in total or
negative symptoms. Collectively, our findings do not support a
subtype of schizophrenia which responds specifically to clozapine.
Greater efficacy of clozapine relative to other antipsychotics was
not dependent on the degree of treatment-resistance, arguing for
its use more generally in schizophrenia.
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